GO
Loading...

Johnson & Johnson

More

  • Stocks End Lower on Bernanke's Warning on Economy Tuesday, 16 Oct 2007 | 4:20 PM ET

    Stocks fell after Fed Chairman Ben Bernanke said the housing slump is likely act as a drag on to U.S. economic growth, sparking investor concerns. "It was just last month Bernanke was saying things were contained, but now he's saying housing troubles can spread," said Brian Hicks, president of Wealth Daily. "This-flip flop in the last month has really spooked the markets."

  • J&J Profit Slips on Costs, Raises Full-Year Target Tuesday, 16 Oct 2007 | 12:49 PM ET

    Health care products maker Johnson & Johnson said Tuesday its third-quarter profit fell about 8 percent because of a charge for cutting jobs, primarily in its stent-making and pharmaceuticals businesses.

  • JNJ, Genentech: What's Ailing Them (And Their Stock) Tuesday, 16 Oct 2007 | 11:44 AM ET

    If you saw the headline, you would've thought that Johnson and Johnson might help power the Dow today. The hybrid pharmaceutical, medical device and consumer healthcare products company handily beat the Street and raised its guidance for the year.

  • Oil Putting Pressure On Markets Tuesday, 16 Oct 2007 | 10:41 AM ET

    How much oil pressure can the stock market take before it blows a gasket? Oil continues to surge into record territory, closing in on $88 per barrel and ready to pump right through $90. Stocks are floundering this morning after weakness in Europe and a down day in Asia. China, though, continues to be the exception with Shanghai stocks once more in record territory.

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • Biogen Expected to Fetch up to $30 Billion Monday, 15 Oct 2007 | 10:11 AM ET

    Biogen Idec, which has put itself up for sale, may get bids of around $25-30 billion from several of the world's top drugmakers keen to expand in the hot area of biotech medicine.

  • Outlook: Investors Bracing For Big Earnings Week Friday, 12 Oct 2007 | 6:15 PM ET

    A slew of companies will be reporting third-quarter results, and investors will be watching not only for the latest figures but what companies predict about future profits.

  • Drugmakers Recall Infant Cold Products Thursday, 11 Oct 2007 | 12:16 PM ET

    Johnson & Johnson , Wyeth  and other makers of infants' nonprescription cough and cold products are recalling certain medicines in the United States because of the danger of overdose, the Consumer Healthcare Products Association said Thursday.

  • Medtronic: The Cents of Making Stents Thursday, 11 Oct 2007 | 10:42 AM ET

    Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.

  • Your Health, Your Trade Wednesday, 10 Oct 2007 | 11:01 PM ET

    BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).

  • Your First Move For Wednesday Oct. 10th Tuesday, 9 Oct 2007 | 9:19 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Vanity Shares Monday, 8 Oct 2007 | 10:57 AM ET

    Companies that make us look good pretty up our wallets too.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • As recession fears recede, investors show an increasing willingness to bet on another interest rate cut from the Federal Reserve.

  • Your First Move For Wednesday Oct. 3rd Wednesday, 3 Oct 2007 | 11:12 AM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Tylenol And The Thalidomide Scares: Moving Forward Tuesday, 2 Oct 2007 | 4:35 PM ET
    Old and new bottles of Tylenol products.

    This week it's 25 years since the first of seven people in Chicagoland died after taking Tylenol laced with cyanide. The scare led to new industry-standard, tamper-resistant over-the-counter drug packaging and became an enduring textbook case for corporate crisis management.

  • Pharmas Reaping Benefits of Weak Dollar Monday, 1 Oct 2007 | 3:18 PM ET

    The Dow is sitting at a new high and you could argue that the move in the pharmaceuticals sector today is largely market related with Dow components Merck, Pfizer and Johnson & Johnson all trading up. As I write this the biggest dollar gainer in the group is Eli Lilly. But the largest percentage gainer is Schering-Plough.

  • Stocks are likely to see further gains in the fourth quarter but the ride may be bumpy.  "October is usually volatile, but we may see a rally in November or December," says Charles Rotblut of Zacks.com.

  • Drugs On TV: My Review Of What's Playing Now Wednesday, 26 Sep 2007 | 8:55 AM ET

    A couple of days home sick with daytime television as your nursemaid can tell you a lot about the current state of multi-billion dollar pharmaceutical advertising. Yeah, we all know it's ubiquitous, but there are at least a couple of noticeable new players and an older one hitting the airwaves.

  • Promising Drug Headlines Tuesday, 25 Sep 2007 | 11:32 AM ET

    Look for pharmaceutical and biotech companies to make news this week as a UBS industry conference kicks off in New York. Also, Merrill Lynch analysts believe pricing power for prescription drugs is returning. What’s the trade?

  • Medicare: We Want Proof On Anemia Drugs Monday, 24 Sep 2007 | 2:56 PM ET

    Right on the heels of my previous blog entry about an analyst saying a Medicare reconsideration of its anemia drug reimbursement policy may be in the offing comes this news out of the agency.